FDA 483 - Exela Pharma Sciences LLC - November 15, 2024

The provided FDA 483 document content is almost entirely redacted, making it impossible to identify the specific company name, inspection dates, main violations or issues observed, or any required actions. The non-redacted portions of the document explain the purpose of the FDA Form 483, noting that it reports objectionable conditions or practices pursuant to Section 704(b) of the Federal Food, Drug, and Cosmetic Act. This section mandates reporting conditions that suggest a product may be adulterated or prepared under insanitary conditions. Without the redacted details, a specific summary of the inspection's findings for a particular entity cannot be generated.